Why We Need CRLIs: Advancing Options for ALS Through Patient Partnerships

Richard S. Bedlack MD PhD Professor of Neurology Director of ALS Program Duke University



1990s-Duke Neurology Residency

- My first encounter with ALS
 - Amazed by the person's story, physical findings
 - Horrified when my attending said "we know what this is called, but we don't know why it happens and there is nothing we can do about it. Go home and get your affairs in order"
 - Decided to stay at Duke and build a new clinic to offer options, research program to offer hope



2001 to Present-Growing Duke ALS Clinic

- Large Multi-Disciplinary Team
 - 2 ALS neurologists, 2 speech therapists, 2 physical therapists, 2 occupational therapists, 2 respiratory therapists, 1 pulmonologist, 1 nutritionist, 1 rehab engineer, 1 social worker/coordinator, 1 research nurse
- Research
 - Genetics, biomarkers, trials
- Lots of patients
 - 250 new patients last year, following 500 patients
- Unique attire, approach

Low Enrollment in ALS Research







Mean ALS trial enrollment rate is 2 patients per site per month

ALS 2008;5:257-265

Not changing much over time

Why This Matters

- Poor enrollment means:
 - Patients are being deprived of the benefits of being in trials
 - Trials take longer, are more expensive, may be terminated without a definitive conclusion
 - Clinical Trials 2010;7:312-321
 - Results may not be generalizable
 - Neurology 2011;77:1432
 - Unless this can be solved, it will take longer than it should to find a cure for ALS

Understanding Low Enrollment

- Not enough options
- Patients disconnected
 - Unaware of or have misconceptions about research options
 - Don't appreciate pre-clinical models, small effect sizes we are looking for, restrictive inclusion criteria, use of placebos, trial travel burdens, or the long time it takes to get results
 - Many "self-experimenting" with alternative and off label treatments (AOTs) and frustrated that doctors not more interested in these
 - Patient quotes



Amyotrophic Lateral Sclerosis



ISSN: 1748-2968 (Print) 1471-180X (Online) Journal homepage: https://www.tandfonline.com/loi/iafd19

Scrutinizing enrollment in ALS clinical trials: Room for improvement?

Richard S. Bedlack, Daniel Pastula, Emily Welsh, Darlene Pulley & Merit E. Cudkowicz

To cite this article: Richard S. Bedlack, Daniel Pastula, Emily Welsh, Darlene Pulley & Merit E. Cudkowicz (2008) Scrutinizing enrollment in ALS clinical trials: Room for improvement?, Amyotrophic Lateral Sclerosis, 9:5, 257-265, DOI: 10.1080/17482960802195913

To link to this article: https://doi.org/10.1080/17482960802195913



Amyotrophic Lateral Sclerosis



ISSN: 1748-2968 (Print) 1471-180X (Online) Journal homepage: https://www.tandfonline.com/loi/iafd19

Modifiable barriers to enrollment in American ALS research studies


Richard S. Bedlack, Paul Wicks, James Heywood & Edward Kasarskis

To cite this article: Richard S. Bedlack, Paul Wicks, James Heywood & Edward Kasarskis (2010) Modifiable barriers to enrollment in American ALS research studies, Amyotrophic Lateral Sclerosis, 11:6, 502-507, DOI: 10.3109/17482968.2010.484494

To link to this article: https://doi.org/10.3109/17482968.2010.484494

Clinical Research Learning Institutes (CRLIs)

- Looked at other fields to see how they were dealing with these same issues
- Heard about and attended a program in Parkinson's disease called Clinical Research Learning Institute, trains patients, family members to better understand research process, opportunities to influence and improve it
- Found ways to engage patients throughout the research process
- This was leading to more studies, improved awareness, studies with better questions, more-patient centric designs, easier consent forms, improved enrollment





ALS CRLIs

- We have held 23 CRLIs thus far
 - Clearwater 2011-2019, 2022
 - Internet 2013, 2020, 2021
 - Philadelphia 2013, 2014, 2019-2022
 - Sacramento 2017
 - Phoenix 2018
 - St. Louis 2018
 - Chicago 2021
 - Canada 2021
- We have trained more than 550 "ALS Research Ambassadors"

PEACe (Patient Education and Advocacy Committee)

- Chairs: Allison Bulat, Nadia Sethi
- Members: All research ambassadors, NEALS clinicians
- Monthly video conferences connecting Research Ambassadors to different stakeholders in ALS research
 - PAGs
 - Sponsors of upcoming, future studies
 - Individual researchers

Ambassadors In Action-Fundraising to Increase Availability





- Played key roles in raising hundreds of millions for research
- Ex. 2 of them started the 2014 ALS Ice Bucket Challenge (\$200M)

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014; 15: 479-480

Ambassadors In Action-Advocating to Increase Research Availability

- Thousands of interactions with members of Congress
 - Helped obtain and maintain funding for National ALS Registry
 - Helped obtain and grow funding for DOD's ALSRP
 - Facilitated Act For ALS in 2021
 - \$500 million in new funds for ALS Research and Expanded Access!



Your comments have been received.

Speaking at the Cherry Hill, NJ Support Group



- Overview
- Why isn't there a cure for ALS?
 What is clinical research?
 Common questions about trials
 Should I participate in research?
 How can I get involved?
- Last month, Karen Delaney Shideleff and I gave our ALS Clinical Research presentation to the Cherry Hill, NI support group. We were grateful to be given the opportunity to share start and the control of the control of the control of the encourage them to evaluate whether participating in research is right for the research start participating in research so right for the control of the co

We both find it very rewarding to be able to educate PALS about this important topic and are particularly inspired wher we receive feedback like this:

[Two weeks after our presentation] "Another gentleman came in [to clinic] all-systems-go for some studies he'd beer

To leave a comment, please click here.

PALS, Advocates and NEALS Research Ambassadors Storm the Hill Posted by: Karen DiGiacomo June 03, 2014



Recently, PALS, advocates and our very own NEALS Research Ambassadors descended on Capitol Hill to educate our Senators and Representatives on this devastating disease called ALS. One by one telling the most personal, emotional, heartbreaking stories to policymakers in the hopes that we will one day fund the means to a cure.



Ambassadors In Action-Improving Study Designs

- 2016 Airlie House ALS Clinical Trial Guidelines
 - International gathering of clinicians, scientists, patients (including ALS Research Ambassadors)
 - Created an evidence and experiencebased guide for optimizing designs of future ALS trials
 - Key suggestions related to engagement:
 - Improved advertising, education
 - Improved compensation
 - Timely notification of results
 - Acknowledgement of participants
 - Publication of results in Open Access form
 - Inviting patients to attend scientific meetings



ALS Clinical Trial Guidelines 2016 meeting in Warrenton, Virginia (USA)



Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Robert H. Baloh, MD, PhD, Michael Benatar, MD, PhD, James D. Berry, MD, Adriano Chio, MD, Philippe Corcia, MD, PhD, Angela Genge, MD, Amelie K. Gubitz, PhD, Catherine Lomen-Hoerth, MD, PhD, Christopher J. McDermott, MD, Erik P. Pioro, MD, PhD, Jeffrey Rosenfeld, MD, PhD, Vincenzo Slani, MD, Martin R. Turner, MBBS, PhD, Markus Weber, MD, Bergamin Rix Brooks, MD, Robert G, Miller, MD, and Hiroshi Missumoto, MD, OSc, for the Airlie House ALS Clinical Trials Guidelines Group

Abstract

To revise the 1999 Airlie House consensus guidelines for the design and implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral sclerosis (ALS).

A consensus committee comprising 140 key members of the international ALS community (ALS researchers, clinicians, patient representatives, research funding representatives, industry, and regulatory agencies) addressed 9 areas of need within ALS research: (1) preclinical studies. (2) biological and phenotypic heterogeneity; (3) outcome measures; (4) disease-modifying and symptomatic interventions; (5) recruitment and retention; (6) biomarkers; (7) clinical tria phases; (8) beyond traditional trial designs; and (9) statistical considerations. Assigned to 1 of 8 sections, committee members generated a draft set of guidelines based on a "background" of developing a (pre)clinical question and a "rationale" outlining the evidence and expert opinion. Following a 2-day, face-to-face workshop at the Airlie House Conference Center, a modified Delphi process was used to develop draft consensus research guidelines, which were sub uently reviewed and modified based on comments from the public. Statistical experts

In this report, we summarize 112 guidelines and their associated backgrounds and rationales. The full list of guidelines, the statistical considerations, and a glossary of terms can be found in data available from Dryad (appendices e-3-e-5, doi.org/10.5061/dryad.32q9q5d). The authors prioritized 15 guidelines with the greatest potential to improve ALS clinical research.

The revised Airlie House ALS Clinical Trials Consensus Guidelines should serve to impro clinical trial design and accelerate the development of effective treatments for patients with ALS.

investigators are listed in the appendix at the end of the article

Ambassadors In Action-Improving Study Designs

- Interacting with ALS researchers to design more attractive, patientfriendly studies
 - Reviewers for TREAT ALS,
 DOD ALSRP grant
 submissions
 - Connecting with funded investigators (ex. Anne Marie Willis, Rick Bedlack)
 - Connecting with Sponsors

PATIENT ADVISORY BOARDS

- MT Pharma
- Biogen
- Cytokinetics
- Avexis
- Patients Like Me
- ALS Untangled
- CReATe Consortium
- HEALEY ALS Platform Trial
- ALS Association
- Patients Like Me
- Corcept Therapeutics
- OSU Medical Center
- > Al Therapeutics

- Al Therapeutics
- Alector
- Cytokinetics
- Clinwiki
- (Picnic Health)
- NURO Corp
- (Annexon)
- (Medicinova)

Ambassadors In Action-Spreading Awareness







ALS Keeps Hope Alive
It's hard to imagine a worse disease than amyotrophic lateral sclerosis, or ALS. The
muscle-wasting affliction strikes about 5,600 patients each year.

DIGITAL/PRENET | BY CHARLOTTE ALBRIGHT




I am starting to see evidence that our efforts work. For the first time our clinic is getting requests about clinical trials from patients. I have been speaking to support groups around our state and it seems to have piqued their interest! I am working with our clinic to make myself available on clinic days to provide information and guidance With the clinical trial process.

- 1000 speeches at at support groups and fundraisers
- 700 interviews, blogs, website posts
- Advising us on better ways to advertise open trials
 - NEALS Trial Search Engine
 - ALS Signal
 - NEALS Trial Concierge
 - National ALS Registry
 Research Notification Tool

Ambassadors In Action-Education

- Support group talks, webinars, Facebook posts, chat room responses, mentoring for other PALS, CALS educating them on research terminology, importance of certain trial design features, common research misconceptions
- Teaching in the CRLI



Ambassadors In Action-Educating on Active, Recently Completed Projects

- CReATe Consortium Podcasts
- ALS Research Paper Review
- Your ALS Guide

lome About CReATe For Patients And Friends For Researchers News Contact Us RDCRN



REATE PODCASTS


♠ FOR PATIENTS AND FRIENDS > CREATE PODCASTS

The CReATe podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.

Episode Title	Podcast Description	Podcast	Date Published
ALS Untangled Series: Ep. 44 - Tamoxifen	Tamoxifen is an FDA approved estrogen receptor modulator that is currently prescribed to treat breast cancer. Here we review surprising evidence that it could someday be an ALS treatment, including its mechanisms of action, pre-clained lata, cases, trials and risks. # als, caregiver, health, mnd, neurology, patient, science, supplement, tamoxifen, treatment	ALS Untangled	2021-07-06 20:06:39
ALS Untangled Series: Ep. 43 - Spirulina (blue green algae)	Spirulina, or blue green algae, is a supplement that is claimed to have antioxidant and anti-inflammatory properties. Here we review the problems we found with the single relevant preclinical ALS study, and some surprising real and potential risks associated with this product. # algae, als, caregiver, health, mnd, neuroscience, patient, science, spirulina, supplement, treatment	ALS Untangled	2021-06-08 15:00:25
ALS Untangled Series: Ep. 42 - Lutimax	Lutimax is a supplement containing Luteolin, a flavonoid that has antioxidant, anti-inflammatory and neuroprotective mechanisms. Here we review case reports and a small trial claiming benefits in people with ALS. # als, health, lutimax, mnd, neurology, patient, treatment	ALS Untangled	2021-05-21 19:24:53
ALS Untangled Series: Ep. 41 - Bee Venom	Bee Venom contains substances that could plausibly affect the rate of ALS progression, and there are some positive (though flawed) preclinical studies and case reports associated with it. Since it has some	ALS Untangled	2021-04-29 16:58:40

Ambassadors In Action-Educating on Alternatives

- ALSUntangled (www.alsuntangled.org)
 - Started 2009
 - Systematically assesses AOTs, toward ultimately helping PALS make more informed decisions
 - Ambassadors have provided ideas for new reviews, optimizing our website



Ambassadors In Action-Accelerating Regulatory Pathway

- Participated (with many others) in creating ALS
 FDA Drug Development Guidance
- Participated (with many others) in recent meetings with FDA, congress related to regulatory aspects of drug development
- Testified at recent FDA hearings on AMX0035
 - Approved in September 2022

BLOG POST from the ALS ASSOCIATION

Case of AMX0035 Proves Advocacy from ALS Community Can Impact Drug Development



Conclusions

- Empowering patients to be partners, rather than subjects, has led to more and better ALS options
- We really are "better together"



Expectations

- Expectations from faculty in this program are to:
 - Teach you about the research process, how to critique a scientific publication, the ALS pipeline, barriers to success, and opportunities for overcoming these barriers via education and advocacy;
 - Lead monthly PEACe
 Calls/Meetings in which you will be presented with research engagement opportunities
 - Be available from now forward to you for questions, suggestions and mentoring.

Expectations

- Expectations from attendees in this program are to:
 - Engage in discussion throughout this program and afterward
 - Read the selected paper and be prepared to weigh in on a critique of it
 - Complete your evaluation form afterward to help us improve the program
 - Become "Research Ambassadors"; In this role, to educate and advocate to/for other PALS, CALS, decision makers and help us design better trials and awareness campaigns
 - Participate in PEACe Meetings
 - Maintain NEALS "tracker" with "contacts" you make, participate in NEALS Research Ambassadors' Facebook page

BY THE NUMBERS Outreach Efforts by Research Ambassadors

1,082

ALS speaking engagement (fundraiser, support group, political event, etc.) 481

Organization of or participation in an ALS event 122

Interview (TV, radio, web or print)

2,633

Speaking or writing to a congressman

78

ALS video (YouTube, social media, webinar, etc.) 455

Creation of or contribution to a website, blog or social media page 83

Published article/column (web or print) 367

Serving on an ALS committee

262

Mentoring (PALS or CALS)

9,208

Otho



Questions

You!

Other Research Ambassadors

Sponsors

Faculty

Thanks